Lung Cancer Update
Episodes
EGFR-Mutant Non-Small Cell Lung Cancer — Year in Review Series on Relevant New Datasets and Advances
27 Apr 2026
Contributed by Lukas
Dr Suresh S Ramalingam and Dr Helena Yu discuss the selection and sequencing of therapy for patients with EGFR mutation-positive non-small cell lung c...
Lung Cancer — 5-Minute Journal Club with Dr Natalie Vokes: Current and Future Role of Tumor-Informed Circulating Tumor DNA Assays
17 Apr 2026
Contributed by Lukas
Dr Natalie Vokes from The University of Texas MD Anderson Cancer Center in Houston discusses recent developments with circulating tumor DNA assays in ...
Extensive-Stage Small Cell Lung Cancer — Current Patterns of Care with First-Line and Maintenance Therapy
27 Feb 2026
Contributed by Lukas
Dr Hossein Borghaei from Fox Chase Cancer Center in Philadelphia, Pennsylvania, and Dr Anne Chiang from Yale Cancer Center in New Haven, Connecticut, ...
Extensive-Stage Small Cell Lung Cancer — What Clinicians Want to Know About First-Line and Maintenance Therapy
17 Dec 2025
Contributed by Lukas
Dr Luis Paz-Ares from the Spanish National Oncology Research Center in Madrid and Dr Shields from Indiana University School of Medicine in Indianapoli...
Lung Cancer — Proceedings from a Symposium Held in Partnership with the American Oncology Network
12 Dec 2025
Contributed by Lukas
Dr Justin F Gainor, Dr Corey J Langer and Dr Misty Dawn Shields summarize the treatment landscape and review relevant clinical datasets for patients w...
HER2-Altered Non-Small Cell Lung Cancer — An Interview with Dr John V Heymach
10 Dec 2025
Contributed by Lukas
Dr John Heymach from The University of Texas MD Anderson Cancer Center in Houston discusses recent updates on available and novel treatment strategies...
Lung Cancer — 5-Minute Journal Club Issue 4 with Dr Aaron Lisberg: Defining the Role of TROP2-Directed Antibody-Drug Conjugates
10 Nov 2025
Contributed by Lukas
Dr Aaron Lisberg from the University of California, Los Angeles, discusses recent developments with TROP2-directed antibody-drug conj...
Lung Cancer — 5-Minute Journal Club Issue 3 with Dr Aaron Lisberg: Defining the Role of TROP2-Directed Antibody-Drug Conjugates
20 Oct 2025
Contributed by Lukas
Dr Aaron Lisberg from the University of California, Los Angeles discusses recent developments with TROP2-directed antibody-drug conjugates in the ma...
Non-Small Cell Lung Cancer — 5-Minute Journal Club Issue 2 with Dr Jacob Sands: Defining the Role of TROP2-Directed Antibody-Drug Conjugates
14 Sep 2025
Contributed by Lukas
Dr Jacob Sands from Dana-Farber Cancer Institute in Boston, Massachusetts, discusses recent developments with TROP2-directed antibody-drug conjugates ...
Small Cell Lung Cancer — Expert Perspectives on Actual Patient Cases
22 Aug 2025
Contributed by Lukas
Dr Stephen V Liu from Georgetown University Hospital in Washington, DC and Dr Charles Rudin from Memorial Sloan Kettering Cancer Center in New York di...
Non-Small Cell Lung Cancer — 5-Minute Journal Club Issue 1 with Dr Jacob Sands: Defining the Role of TROP2-Directed Antibody-Drug Conjugates
18 Aug 2025
Contributed by Lukas
Dr Jacob Sands from Dana-Farber Cancer Institute in Boston, Massachusetts, discusses recent developments with TROP2-directed antibody-drug conjugates ...
Non-Small Cell Lung Cancer — Year in Review Series on Relevant New Datasets and Advances
08 Aug 2025
Contributed by Lukas
Dr Benjamin Levy from Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial in Washington, DC, discusses important efficacy and safety data fro...
Lung Cancer — Proceedings from a Session Held During the 2025 ASCO Annual Meeting on the Current and Future Role of Immunotherapy and Antibody-Drug Conjugates
17 Jul 2025
Contributed by Lukas
Prof Marina Garassino, Dr John Heymach, Prof Solange Peters and moderator Dr Jacob Sands present key data from the ASCO 2025 Annual Meeting on the man...
For Oncology Nurses: DLL3-Targeting Bispecific T-Cell Engagers for Small Cell Lung Cancer — Proceedings from the 2025 Annual ONS Congress
08 Jul 2025
Contributed by Lukas
Dr Anne Chiang, Dr Erin Schenk, and nurse practitioners Ms Elizabeth Krueger and Ms Beth Sandy discuss the role of bispecific antibodies in the manage...
EGFR Mutation-Positive Non-Small Cell Lung Cancer — Proceedings from a Session Held During the 2025 ASCO Annual Meeting
20 Jun 2025
Contributed by Lukas
Prof Nicolas Girard, Dr Jonathan Goldman, Dr Pasi Jänne, Dr Suresh Ramalingam, Dr Joshua Sabari and moderator Dr Helena Yu present data informing tre...
Non-Small Cell Lung Cancer and Therapeutic Targets Beyond EGFR — Year in Review Series on Relevant New Datasets and Advances
10 Jun 2025
Contributed by Lukas
Dr Jessica J Lin from Massachusetts General Hospital in Boston and Dr Joel W Neal from Stanford Cancer Institute in California summarize major treatme...
Immunotherapy and Nontargeted Approaches for NSCLC — Fourth Annual National General Medical Oncology Summit
18 May 2025
Contributed by Lukas
Clinical investigators discuss available data guiding the management of non-small cell lung cancer with immunotherapy and other nontargeted approaches...
EGFR Mutation-Positive NSCLC — Fourth Annual National General Medical Oncology Summit
30 Apr 2025
Contributed by Lukas
Clinical investigators discuss available data guiding the management of EGFR mutation-positive non-small cell lung cancer. CME information and...
For Oncology Nurses: Antibody-Drug Conjugates for Breast Cancer and Lung Cancer — Proceedings from the 2025 Annual ONS Congress
26 Apr 2025
Contributed by Lukas
Dr Edward B Garon, Dr Tiffany A Traina, and nurse practitioners Ms Marianne J Davies and Ms Marissa Marti-Smith discuss the role of antibody-drug conj...
First-Line Therapy for Metastatic Non-Small Cell Lung Cancer and an ALK Rearrangement — An Interview with Dr Justin F Gainor
10 Apr 2025
Contributed by Lukas
Dr Justin F Gainor from Massachusetts General Hospital in Boston reviews available clinical data on ALK inhibitors and first-line treatment strategies...
EGFR-Mutant Non-Small Cell Lung Cancer — Year in Review Series on Relevant New Datasets and Advances
06 Feb 2025
Contributed by Lukas
Dr Enriqueta Felip from the Vall d’Hebron Institute of Oncology in Barcelona, Spain, and Dr Helena Yu from Memorial Sloan Kettering Cancer Center in...
Cases from the Community: Integrating New Research Findings into Current Practice — Lung Cancer
13 Dec 2024
Contributed by Lukas
Dr Edward B Garon shares his perspectives on the evolving therapeutic landscape for patients with lung cancer.
Meet The Professor: Current and Future Use of Nontargeted Therapy for Metastatic Non-Small Cell Lung Cancer — A 2024 World Conference on Lung Cancer
11 Dec 2024
Contributed by Lukas
Dr Heather Wakelee from Stanford University School of Medicine in California discusses the implications of recent datasets for the current and future ...
The Implications of Recent Datasets for the Current and Future Management of Lung Cancer — A Review of Information from ESMO Congress 2024 and Other Conferences
25 Nov 2024
Contributed by Lukas
Dr Suresh S Ramalingam from the Emory University School of Medicine in Atlanta, Georgia and Dr Gregory J Riely from Memorial Sloan Kettering Cancer Ce...
Data + Perspectives: Clinical Investigators Explore the Application of Recent Datasets in Current Oncology Care — Lung Cancer
16 Nov 2024
Contributed by Lukas
Specialist clinical investigators share their perspectives on the evolving therapeutic landscape for patients with lung cancer.
Oncology Today with Dr Neil Love: Special Edition — Key Presentations on Lung Cancer from Recent Major Conferences
07 Nov 2024
Contributed by Lukas
Dr Stephen V Liu from Georgetown University Hospital in Washington, DC, reviews recently presented data with and newly approved therapies for localize...
The Implications of Recent Datasets for the Current and Future Management of Small Cell Lung Cancer — A 2024 World Conference on Lung Cancer Review
23 Oct 2024
Contributed by Lukas
Dr Jacob Sands from the Dana-Farber Cancer Institute in Boston, Massachusetts, discusses recent presentations on approved and investigational therapie...
The Implications of Recent Datasets for the Current and Future Use of Nontargeted Therapy for Metastatic Non-Small Cell Lung Cancer
16 Oct 2024
Contributed by Lukas
Dr Edward Garon from UCLA Health Jonsson Comprehensive Cancer Center and Dr Luis Paz-Ares from the Spanish National Oncology Research Center in Madrid...
The Implications of Recent Datasets for the Current and Future Management of Non-Small Cell Lung Cancer with Actionable Targets Beyond EGFR
08 Oct 2024
Contributed by Lukas
Dr Ibiayi Dagogo-Jack from Massachusetts General Hospital in Boston and Dr Corey J Langer from the Abramson Cancer Center in Philadelphia, Pennsylvani...
The Implications of Recent Datasets for the Current and Future Management of Non-Small Cell Lung Cancer with EGFR Mutations
02 Oct 2024
Contributed by Lukas
Dr Joshua K Sabari from the NYU Langone Health Perlmutter Cancer Center and Dr Helena Yu from Memorial Sloan Kettering Cancer Center in New York, New ...
Inside the Issue: Optimizing the Diagnosis and Treatment of Neuroendocrine Tumors
19 Sep 2024
Contributed by Lukas
Dr Pamela Kunz from the Yale School of Medicine and Yale Cancer Center in New Haven, Connecticut, and Dr Simron Singh from the Odette Cancer Centre an...
Striving for Consensus: Current and Future Management of Non-Small Cell Lung Cancer with an EGFR Mutation
12 Sep 2024
Contributed by Lukas
Dr Pasi Jänne from the Dana-Farber Cancer Institute in Boston, Massachusetts, Prof Tom John from the Peter MacCallum Cancer Centre in Melbourne, Aust...
Inside the Issue: Integrating ALK-Targeted Therapy into the Management of Localized Non-Small Cell Lung Cancer
21 Aug 2024
Contributed by Lukas
Prof Solange Peters from the Lausanne University Hospital in Lausanne, Switzerland, and Professor Ben Solomon from the Peter MacCallum Cancer Centre i...
Oncology Today with Dr Neil Love: Novel Agents and Strategies in Lung Cancer
14 Aug 2024
Contributed by Lukas
Dr Melissa Johnson from Sarah Cannon Research Institute in Nashville, Tennessee, Dr Ticiana Leal from Winship Cancer Institute of Emory University in ...
Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Immunotherapy and Other Nontargeted Approaches for Lung Cancer
05 Aug 2024
Contributed by Lukas
Dr Matthew Gubens from the University of California, San Francisco summarizes important 2023 datasets guiding the use of immunotherapy and other nonta...
Oncology Today with Dr Neil Love: An interview with Jonathan W Goldman, MD — Management of Non-Small Cell Lung Cancer with an EGFR Mutation
25 Jul 2024
Contributed by Lukas
Dr Jonathan W Goldman from UCLA Health in Santa Monica, California summarizes recent developments presented at ASCO 2024 for patients with non-small c...
Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Targeted Therapy for Non-Small Cell Lung Cancer
12 Jun 2024
Contributed by Lukas
Dr Justin F Gainor from Massachusetts General Hospital in Boston and Dr Karen Reckamp from Cedars-Sinai Center in Los Angeles, California, summarize r...
Oncology Today with Dr Neil Love: The Emerging Role of B7-H3-Targeted Antibody-Drug Conjugates
04 Apr 2024
Contributed by Lukas
Dr Manish Patel from the Florida Cancer Specialists & Research Institute in Sarasota, Florida, discusses drug development, early-phase clinical tr...
Oncology Today with Dr Neil Love: Promising Therapeutic Strategies for Patients with Progressive Metastatic Non-Small Cell Lung Cancer
20 Mar 2024
Contributed by Lukas
Dr Melissa Johnson from Sarah Cannon Research Institute in Nashville, Tennessee, discusses available data with antibody-drug conjugates with establish...
Implications of Recent Data Sets for the Current and Future Management of Lung Cancer
11 Dec 2023
Contributed by Lukas
Dr Luis Paz-Ares from the National Oncology Research Center in Madrid, Spain, Dr Zofia Piotrowska from Massachusetts General Hospital in Boston, and D...
Inside the Issue: Integrating Targeted and Immunotherapy into the Management of Localized Non-Small Cell Lung Cancer
16 Oct 2023
Contributed by Lukas
Dr Jamie Chaft and Dr John Heymach discuss the optimal integration of targeted therapy and immunotherapy into the care of patients with localized non-...
Striving for Consensus: Current and Future Management of Metastatic Non-Small Cell Lung Cancer in Patients Who Experience Disease Progression on Immune Checkpoint Inhibitor Therapy
08 Sep 2023
Contributed by Lukas
Dr Corey Langer, Dr Ticiana Leal, Dr Karen Reckamp and Dr Jacob Sands discuss the optimal current management of relapsed NSCLC and provide perspective...
Oncology Today with Dr Neil Love: Special Edition — Key Presentations on Lung Cancer from the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
22 Aug 2023
Contributed by Lukas
Featuring a discussion on key presentations on lung cancer from the 2023 ASCO Annual Meeting, with Dr Matthew Gubens, moderated by Dr Neil Love.
Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Immunotherapy and Other Nontargeted Approaches for Lung Cancer
01 May 2023
Contributed by Lukas
Proceedings from our Year in Review webinar on immunotherapy and other nontargeted approaches for lung cancer. Featuring perspectives from Drs Luis Pa...
Recent Advances and Future Directions in Lung Cancer — With Dr Ibiayi Dagogo-Jack and Stephen Liu (Proceedings from a Symposium in Partnership with NCOA and SCOS)
17 Mar 2023
Contributed by Lukas
Proceedings from a daylong symposium hosted in partnership with North Carolina Oncology Association and the South Carolina Oncology Society, featuring...
Striving for Consensus on the Management of ALK-Positive Lung Cancer
06 Mar 2023
Contributed by Lukas
Featuring a discussion on the management of ALK-positive lung cancer with Dr Ross Camidge, Dr Justin Gainor, Prof Solange Peters and Prof Ben Solomon,...
Oncology Today with Dr Neil Love: Management of HER2-Altered Non-Small Cell Lung Cancer?
21 Feb 2023
Contributed by Lukas
Featuring a discussion on targeted therapy for HER2-altered non-small cell lung cancer with Dr Bob Li, moderated by Dr Neil Love.
Oncology Today with Dr Neil Love: Management of Metastatic Non-Small Cell Lung Cancer without an Actionable Mutation
13 Feb 2023
Contributed by Lukas
Featuring a discussion on new and emerging data in the management of NSCLC without an actionable mutation, with Dr Edward Garon, moderated by Dr Neil ...
Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Targeted Therapy for Non-Small Cell Lung Cancer
24 Jan 2023
Contributed by Lukas
Proceedings from our Year in Review webinar on targeted therapy for non-small cell lung cancer. Featuring perspectives from Drs Zofia Piotrowska and G...